Nirogacestat and Famotidine not checked
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “oral dose of 150 mg nirogacestat \& oral dose of 40 mg famotidine”In the company’s words, NCT07171619 on ClinicalTrials.gov
- Main trialPhase 1
- “This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants”In the company’s words, NCT07171619 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 10 Nov 2025 | Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026